Adipose-derived stem cells: an upcoming novel therapeutic in the management of Erectile dysfunction post radical prostatectomy in prostate cancer patients

Gargi Digholkar,Ryan Varghese,Kavita Pal,Rohit Sharma
DOI: https://doi.org/10.1038/s41443-024-00866-x
2024-03-06
International Journal of Impotence Research
Abstract:Globally, prostate cancer (PC) is one of the most prevalent cancers and ranks as the fourth most diagnosed cancer in men. In 2020 alone, over 1.4 million individuals were diagnosed with PC. Contrary to popular perceptions associating PC with men aged 65 years or older, recent statistics underscore that over 10% of recent diagnoses in the United States are in men aged <55 years [1]. Although most men with early onset PC are diagnosed with low-risk diseases, the trajectory of their life expectancy is greatly influenced by prolonged side effects from treatment, poor quality of life (QoL) after treatment, and a protracted vulnerability to relapse and disease progression, which may even be fatal [2]. Definitive treatment modalities for localized PC include cryotherapy, hormone therapy, radiation therapy, and radical prostatectomy (RP). Nevertheless, each of these interventions is ridden by limitations, ultimately affecting the QoL of the patient. The choice of treatment depends on a slew of variables including disease severity, patient preferences, comorbidities, and age.
urology & nephrology
What problem does this paper attempt to address?